- Reuters•6 hours ago
Alere claims in its complaint that Abbott has avoided responding to a second request by the Federal Trade Commission in a bout of "buyer's remorse" spurred by a desire to free up capital for Abbott's other major planned deal - a $24 billion acquisition of rival St. Jude Medical (STJ.N). Abbott denied the allegations, arguing that Alere's financial problems and related delays in filing its financial statements had slowed the deal's progress. Abbott also said it had been approached by a whistleblower who alleges that Alere is deliberately hiding information about its Indian operations.
- TheStreet.com•10 hours ago
In a newly unsealed lawsuit, Alere (ALR) claims that Abbott (ABT) blocked the companies' $7.9 billion merger once it experienced 'buyer's remorse.'
Abbott Laboratories (ABT)
NYSE - NYSE Real Time Price. Currency in USD
|Bid||41.97 x 200|
|Ask||42.09 x 300|
|Day's Range||41.93 - 42.98|
|52wk Range||36.00 - 46.38|
|1y Target Est||N/A|
Trade prices are not sourced from all markets
|P/E Ratio (ttm)||27.74|
|Avg Vol (3m)||10,383,138|
|Dividend & Yield||1.04 (2.40%)|